Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results of NCIC CTG MA.31

Journal of Clinical Oncology

Volumn 33, Issue 14, 2015, Pages 1574-1583

  Gelmon, Karen A ^a   Boyle, Frances M ^h   Kaufman, Bella ⁱ   Huntsman, David G ^j   Manikhas, Alexey ^k   Di Leo, Angelo ⁿ   Martin, Miguel ^o   Schwartzberg, Lee S ^p   Lemieux, Julie ^b   Aparicio, Samuel ^a   Shepherd, Lois E ^c   Dent, Susan ^d   Ellard, Susan L ^a   Tonkin, Katia ^g   Pritchard, Kathleen I ^e   Whelan, Timothy J ^f   Nomikos, Dora ^c   Nusch, Arnd ^q   Coleman, Robert E ^r   Mukai, Hirofumi ^s   Tjulandin, Sergei ^l   Khasanov, Rustem ^m   Rizel, Shulamith ^j   Connor, Anne P ^t   Santillana, Sergio L ^u   Chapman, Judith Anne W ^c   Parulekar, Wendy R ^c   more..

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^f JURAVINSKI CANCER CENTRE   (Canada)

^g CROSS CANCER INSTITUTE   (Canada)

^h Mater Hospital   (Australia)

ⁱ SHEBA MEDICAL CENTER   (Israel)

^j RABIN MEDICAL CENTER   (Israel)

^k City Clinical Oncological Dispensery   (Russian Federation)

^l N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^m Republican Clinical Oncological Dispensary   (Russian Federation)

ⁿ Sandro Pitigliani Medical Oncology Unit   (Italy)

^o HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^p WEST CLINIC   (United States)

^q Praxis   (Germany)

^r WESTON PARK HOSPITAL   (United Kingdom)

^s NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^t GLAXOSMITHKLINE   (United States)

^u Estrada dos Bandeirantes   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; TAXANE; TAXOID; TUMOR MARKER;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGY; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER MORTALITY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE FAILURE; HEPATOBILIARY DISEASE; HUMAN; LIVER DYSFUNCTION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SKIN ULCER; TREATMENT OUTCOME; VOMITING; AGED; BREAST NEOPLASMS; CANCER STAGING; CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG ERUPTIONS; FOLLOW UP; INTERNATIONAL COOPERATION; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; QUALITY OF LIFE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL COOPERATION; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; QUALITY OF LIFE; QUINAZOLINES; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84933564599     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.9590     Document Type: Article

References (34)

1. Burstein HJ: The distinctive nature of HER2 positive breast cancer. N Engl J Med 353:1652-1654, 2005
2. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
3. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II of the efficacy and safety of trastuzumab combined with docetaxel in patients with epidermal growth factor receptor 2-positive metastatic breast cancer administered as first line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005
4. Robert N, Leyland-Jones B, Asmar L, et al: Randomized phase III study of trastuzumab, paclitaxel and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786-2792, 2006
5. Valero V, Forbes J, Pegram MD, et al: Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2 gene-amplified metastatic breast cancer (BCIRG 007 study): Two highly active therapeutic regimens. J Clin Oncol 29:149-156, 2011
6. Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer. N Engl J Med 353:1659-1672, 2005
7. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer. N Engl J Med 353:1673-1684, 2005
8. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
9. Smith I, Marion P, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer: A randomized controlled trial. Lancet 369:29-36, 2007
10. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
11. Spector NL, Xia W, Burris H 3rd, et al: Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23:2502-2512, 2005
12. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2 positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
13. Cameron D, Casey M, Press M, et al: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:3533-3543, 2008
14. Di Leo A, Gomez HL, Aziz Z, et al: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544-5552, 2008
15. Guan Z, Xu B, Desilvio ML, et al: Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2- overexpressing metastatic breast cancer. J Clin Oncol 31:1947-1953, 2013
16. Blackwell KL, Burstein HJ, Storniolo AM, et al: Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 Study. J Clin Oncol 30:2585-2592, 2012
17. Bachelot T, Romieu G, Campone M, et al: Laptinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study. Lancet Oncol 14:64-71, 2013
18. Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 379:633-640, 2012
19. Untch M, Loibl S, Bischoff J, et al: Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane based chemotherapy (GeparQuinto, GBG 44): A randomized phase 3 trial. Lancet Oncol 13:135-144, 2012
20. ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study: BIG 2-06/N063D. https://clinicaltrials.gov/ct2/show/NCT00490139
21. Tu D: Minimization procedure, in Chow SC (ed): Encyclopedia of Biopharmaceutical Statistics (ed 3). New York, NY, Marcel Dekker, 2010, pp 795-798
22. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). J Natl Cancer Inst 92:205-216, 2000
23. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
24. Altman DG, McShane LM, Sauerbrei W, et al: Reporting recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and elaboration. PLoS Med 9:e1001216, 2012
25. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010
26. DiRienzo AG, Lagakos SW: Bias correction for score tests arising from misspecified proportional hazard regression models. Biometrika 88:421-434, 2001
27. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
28. Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/neu-Positive Metastatic Breast Cancer. http://clinicaltrials.gov/ct2/show/results/NCT00667251?sect=X40156#othr
29. Gelmon K, Boyle F, Kaufman B, et al: Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA. 31/GSK EGF 108919. J Clin Oncol 30, 2012 (suppl; abstr LBA671)
30. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
31. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2 positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012
32. Piccart-Gebhart MJ, Holmes AP, Baselga J, et al: First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol 32:4s, 2014 (suppl; abstr LBA4)
33. Dawood S, Broglio K, Ensor J, et al: Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 21:2169-2174, 2010
34. Pivot X, Semiglazov V, Zurawsky B, et al: CEREBAL(EGF111438): An open label randomized phase III study comparing the incidence of CNS metastases in patients(pts) with HER2+ metastatic breast cancer (MBC), treated with lapatinib plus capecitabine (LC) versus trastuzumab plus capecitabine (TC). Ann Oncol 23:ixe1-ixe30, 2012 (suppl 9)